2018
DOI: 10.1101/405845
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Genotype-Phenotype Relations of the von Hippel-Lindau Tumor Suppressor Inferred from a Large-Scale Analysis of Disease Mutations and Interactors

Abstract: Familiar cancers represent a privileged point of view for studying the complex cellular events inducing tumor transformation. Von Hippel-Lindau syndrome, a familiar predisposition to develop cancer is a clear example. Here, we present our efforts to decipher the role of von Hippel-Lindau tumor suppressor protein (pVHL) in cancer insurgence. We collected high quality information about both pVHL mutations and interactors to investigate the association between patient phenotypes, mutated protein surface and impai… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

2
12
0

Year Published

2019
2019
2022
2022

Publication Types

Select...
6
2

Relationship

3
5

Authors

Journals

citations
Cited by 9 publications
(14 citation statements)
references
References 77 publications
2
12
0
Order By: Relevance
“…Kidney-specific pVHL inactivation causes the development of kidney cysts in a mouse model [ 28 ], while reintroduction of a wild-type gene interrupts malignant progression [ 29 ]. Nevertheless, pVHL somatic inactivation is calculated to affect about 75% of sporadic clear cell renal cell carcinomas (ccRCC) [ 30 , 31 ], while a number of studies suggests a role for pVHL in the regulation of the cellular tumour antigen p53 (p53) [ 32 – 34 ].…”
Section: Introductionmentioning
confidence: 99%
“…Kidney-specific pVHL inactivation causes the development of kidney cysts in a mouse model [ 28 ], while reintroduction of a wild-type gene interrupts malignant progression [ 29 ]. Nevertheless, pVHL somatic inactivation is calculated to affect about 75% of sporadic clear cell renal cell carcinomas (ccRCC) [ 30 , 31 ], while a number of studies suggests a role for pVHL in the regulation of the cellular tumour antigen p53 (p53) [ 32 – 34 ].…”
Section: Introductionmentioning
confidence: 99%
“…The prototypic VHL disease type 2A (p.Tyr98His) and type 2B (p.Arg167Trp/p.Arg167GLn) mutations (see Table 2) disrupt respectively the HIF-1α/ÎČ-domain and the elongin C/α-domain binding sites. In a recent study, Minervini et al [51] used computational modelling to propose that five different interfaces of pVHL can be delineated and, using published data from 360 VHL mutations and 59 proposed pVHL interactors, they attempted to correlate the phenotypic effects of VHL missense variants with their effect on the various interactors. These findings will provide a framework for functional studies aimed at determining the molecular basis for the complex genotype-phenotype correlations observed in VHL disease and VHL-related polycythaemia disorders.…”
Section: Pvhl Function and Oncogenic Drivers Of Tumourigenesismentioning
confidence: 99%
“…CUPSAT uses protein structure to make fast and accurate ΔΔG predictions from 494 environment-specific atomic and torsion angle potentials. The high speed of CUPSAT predictions 495 lends itself to analyses of diseases associated with a large number of missense mutations [43]. 496…”
Section: Protein-protein Interaction Modeling 470mentioning
confidence: 99%